Finoriq research workspace
Anika Therapeutics, Inc. (ANIK) SEC Filings & Filing Highlights
Anika Therapeutics, Inc. offers osteoarthritis (OA) pain management products and services, such. Review ANIK SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
- Company
- Anika Therapeutics, Inc. (ANIK)
- Ticker
- ANIK
- Market Cap
- $200.6M
- Latest Price
- $15.08
- Industry
- Medical Devices
Anika Therapeutics, Inc. (ANIK) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Anika Therapeutics, Inc. (ANIK).
| Event | Form | Date |
|---|---|---|
| The matters considered and voted on by the stockholders at the Annual Meeting and the votes of...The Company held the Annual Meeting on June 18, 2026. The Board solicited proxies for the Annual Meeting pursuant to the Proxy Statement, a... | 8-K5.07 | 2026-06-23 |
| Sixth Amendment and Restatement of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan On...Sixth Amendment and Restatement of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan On April 26, 2026, the board of directors, or t... | 8-K5.02 | 2026-06-23 |
| On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the “B...On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the “Board”) of the Company, and Glenn R. Larsen,... | 8-K5.02 | 2026-04-29 |
| Anika Therapeutics, Inc.: Earnings or resultsOn April 29, 2026, Anika Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter e... | 8-K2.02 | 2026-04-29 |
| On February 26, 2026, the Company and Mr. Colleran entered into a Transitional Services and Gen...On February 26, 2026, the Company and Mr. Colleran entered into a Transitional Services and General Release of Claims Agreement (the “Trans... | 8-K5.02 | 2026-02-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.